Business Description
![Resverlogix Corp Resverlogix Corp logo](https://static.gurufocus.com/logos/0C00000IC5.png?14)
Resverlogix Corp
NAICS : 325414
SIC : 3741
ISIN : CA76128M1086
Compare
Compare
Traded in other countries / regions
RVX.CanadaRVXCF.USARFS.Germany0VF9.UK IPO Date
2005-01-17Description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | -10.22 | |||||
Debt-to-Equity | -0.12 | |||||
Debt-to-EBITDA | -1.16 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 29.8 | |||||
3-Year FCF Growth Rate | 49 | |||||
3-Year Book Growth Rate | 4.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 91.05 | |||||
9-Day RSI | 83.56 | |||||
14-Day RSI | 78.18 | |||||
6-1 Month Momentum % | -16.67 | |||||
12-1 Month Momentum % | -47.37 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.07 | |||||
Quick Ratio | 0.05 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.8 | |||||
Shareholder Yield % | -4.84 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -144.89 | |||||
ROIC % | -45.52 | |||||
ROC (Joel Greenblatt) % | -6240.33 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -3.28 | |||||
EV-to-EBITDA | -3.49 | |||||
EV-to-FCF | -6.83 | |||||
Earnings Yield (Greenblatt) % | -30.49 | |||||
FCF Yield % | -21.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Resverlogix Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | |||
EPS (TTM) (C$) | -0.063 | ||
Beta | 1.29 | ||
Volatility % | 29.86 | ||
14-Day RSI | 78.18 | ||
14-Day ATR (C$) | 0.005841 | ||
20-Day SMA (C$) | 0.066 | ||
12-1 Month Momentum % | -47.37 | ||
52-Week Range (C$) | 0.04 - 0.09 | ||
Shares Outstanding (Mil) | 276.97 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Resverlogix Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Resverlogix Corp Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Resverlogix Corp Frequently Asked Questions
What is Resverlogix Corp(TSX:RVX)'s stock price today?
The current price of TSX:RVX is C$0.09. The 52 week high of TSX:RVX is C$0.09 and 52 week low is C$0.04.
When is next earnings date of Resverlogix Corp(TSX:RVX)?
The next earnings date of Resverlogix Corp(TSX:RVX) is 2024-11-08 Est..
Does Resverlogix Corp(TSX:RVX) pay dividends? If so, how much?
Resverlogix Corp(TSX:RVX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |